New Stock News | ACROBIOSYSTEMS plans Hong Kong IPO with revenue exceeding 600 million yuan in the first three quarters
ACROBIOSYSTEMS announced on October 29th its plan to conduct an H-share IPO on the Hong Kong Stock Exchange to promote its internationalization strategy. The company's revenue for the first three quarters reached 613 million yuan, a year-on-year increase of 32.3%; the net profit attributable to the parent company was 132 million yuan, a year-on-year increase of 58.6%. The company focuses on biotechnology, with its main business including the research and development, production, and sales of biopharmaceuticals, involving drug development and optimization for various diseases
According to Zhitong Finance APP, on October 29, ACROBIOSYSTEMS (301080.SZ) announced that in order to further promote the implementation of its internationalization strategy, the company plans to issue shares (H shares) overseas and list on the Hong Kong Stock Exchange. The company's board of directors has authorized the management to initiate the relevant preparatory work for this H share issuance and listing. As of now, the relevant details of this H share issuance and listing have not yet been determined.
According to the information, ACROBIOSYSTEMS focuses on the biotechnology field, with its main business including the research and development, production, and sales of biopharmaceuticals, dedicated to providing high-quality biological products and services for the medical industry. In addition, the company is also involved in the innovative application of biotechnology.
The company's main products and services are applied in the early detection and validation of drugs for diseases such as tumors, autoimmune diseases, cardiovascular diseases, and infectious diseases, as well as drug screening and optimization, development and optimization of diagnostic reagents, preclinical experiments and clinical trials, and drug production processes and process control (CMC) in the research and production stages.
ACROBIOSYSTEMS' Q3 2025 report shows that in the first three quarters, the company's operating income was 613 million yuan, an increase of 32.3% year-on-year; net profit attributable to the parent company was 132 million yuan, an increase of 58.6% year-on-year; net profit attributable to the parent company after deducting non-recurring gains and losses was 133 million yuan, an increase of 58.8% year-on-year; net cash flow from operating activities was 177 million yuan, an increase of 99.5% year-on-year; EPS (fully diluted) was 0.789 yuan
